AC Immune SA (ACIU) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) Comparing side by side

AC Immune SA (NASDAQ:ACIU) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AC Immune SA N/A 0.00 N/A -0.53 0.00
Corbus Pharmaceuticals Holdings Inc. 5.76M 79.26 70.21M -0.87 0.00

Demonstrates AC Immune SA and Corbus Pharmaceuticals Holdings Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 provides AC Immune SA and Corbus Pharmaceuticals Holdings Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
AC Immune SA 0.00% -25.2% -22.4%
Corbus Pharmaceuticals Holdings Inc. -1,218.92% -88.5% -71.2%


The Current Ratio of AC Immune SA is 19.2 while its Quick Ratio stands at 19.2. The Current Ratio of rival Corbus Pharmaceuticals Holdings Inc. is 3.5 and its Quick Ratio is has 3.5. AC Immune SA is better equipped to clear short and long-term obligations than Corbus Pharmaceuticals Holdings Inc.

Analyst Ratings

AC Immune SA and Corbus Pharmaceuticals Holdings Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AC Immune SA 0 0 0 0.00
Corbus Pharmaceuticals Holdings Inc. 0 0 5 3.00

Meanwhile, Corbus Pharmaceuticals Holdings Inc.’s consensus price target is $26.2, while its potential upside is 270.06%.

Insider & Institutional Ownership

The shares of both AC Immune SA and Corbus Pharmaceuticals Holdings Inc. are owned by institutional investors at 32.2% and 41.9% respectively. Insiders owned 52.69% of AC Immune SA shares. On the other hand, insiders owned about 3.4% of Corbus Pharmaceuticals Holdings Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AC Immune SA 2.88% 12.62% -58.61% -45.67% -55.77% -50.9%
Corbus Pharmaceuticals Holdings Inc. -29.27% -19.44% -10.31% 10.73% -16% 4.28%

For the past year AC Immune SA had bearish trend while Corbus Pharmaceuticals Holdings Inc. had bullish trend.


AC Immune SA beats on 6 of the 10 factors Corbus Pharmaceuticals Holdings Inc.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.